Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PTC Therapeutics's gross profit for the
three
months ended in Jun. 2026 was $341 Mil. PTC Therapeutics's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $938 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. PTC Therapeutics's gross profit for the
three
months ended in Jun. 2026 was $341 Mil. PTC Therapeutics's Revenue for the
three
months ended in Jun. 2026 was $361 Mil. Therefore, PTC Therapeutics's Gross Margin % for the quarter that ended in Jun. 2026 was 94.47%.
PTC Therapeutics had a gross margin of 94.47% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of PTC Therapeutics was 97.65%. The lowest was 92.89%. And the median was 95.03%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
PTC Therapeutics had a gross margin of 94.47% for the quarter that ended in Jun. 2026 => Durable competitive advantage
PTC Therapeutics Gross Profit Related Terms
PTC Therapeutics Gross Profit Historical Data
* Premium members only.
The historical data trend for PTC Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PTC Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $938 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
PTC Therapeutics (PTCT) has a Gross Profit of $938 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Gross Profit too high?
PTC Therapeutics' current Gross Profit is $938 Mil. Overall, PTC Therapeutics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Gross Profit compare to XENE and CGON?
PTC Therapeutics' Gross Profit of $938 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Gross Profit is $938 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, PTC Therapeutics (PTCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $37.81, compared to a current price of $69.82 — trading 84.7% above its estimated fair value. The current Gross Profit is $938 Mil. PTC Therapeutics' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For PTC Therapeutics (PTCT), the current Gross Profit is $938 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTC Therapeutics (PTCT) Overvalued in 2026?
Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued.
The current stock price of $69.82 is trading 84.7% above its estimated GF Value™ of $37.81.
GuruFocus considers PTC Therapeutics to be Significantly Overvalued.
Key valuation signals for PTCT:
Gross Profit: $938 Mil
GF Value™: $37.81 vs. price of $69.82 (84.7% above fair value)
No single metric tells the full story. See the PTCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
53GF Score
Get the complete analysis for PTCT
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTCT has been successfully added to your 
